|
gptkbp:instanceOf
|
gptkb:drug
PARP inhibitor
|
|
gptkbp:approvalYear
|
2017
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01XX54
|
|
gptkbp:bioavailability
|
73%
|
|
gptkbp:brand
|
gptkb:Zejula
|
|
gptkbp:CASNumber
|
1038915-60-4
|
|
gptkbp:category
|
small molecule
antineoplastic agent
orphan drug
|
|
gptkbp:chemicalFormula
|
C19H20N4O
|
|
gptkbp:contraindication
|
hypersensitivity to niraparib
|
|
gptkbp:developer
|
gptkb:Tesaro
GlaxoSmithKline
|
|
gptkbp:eliminationHalfLife
|
36 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasSMILES
|
CC1=NN=C(N1)N2CCN(CC2)C3=CC=CC=C3C(=O)NC4=CC=CC=C4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Niraparib
|
|
gptkbp:indication
|
maintenance treatment of recurrent ovarian cancer
treatment of advanced ovarian cancer with HRD positive status
|
|
gptkbp:KEGGID
|
D10410
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
PARP enzyme inhibition
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
320.39 g/mol
|
|
gptkbp:patent
|
gptkb:Tesaro
GlaxoSmithKline
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:pregnancyWarning
|
may cause fetal harm
|
|
gptkbp:proteinBinding
|
83%
|
|
gptkbp:PubChem_CID
|
gptkb:DB11709
24958200
CHEMBL2068659
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
constipation
fatigue
insomnia
thrombocytopenia
|
|
gptkbp:storage
|
20°C to 25°C
|
|
gptkbp:UNII
|
3XNW2WA2W5
|
|
gptkbp:usedFor
|
gptkb:cancer
gptkb:fallopian_tube_cancer
primary peritoneal cancer
|
|
gptkbp:bfsParent
|
gptkb:PARP1
gptkb:PARP2
gptkb:SF-2281
|
|
gptkbp:bfsLayer
|
7
|